Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook

Abbott Laboratories (NYSE:ABT) ranks among the top picks for a retirement portfolio. UBS maintained Abbott Laboratories (NYSE:ABT) as a top choice in the Medical Supplies and Devices industry on September 23, reaffirming its Buy rating on the company’ shares with a price target of $154. The firm expressed strong confidence in the company’s future trajectory, with particular focus on Abbott’s MedTech division, which it believes can maintain growth rates of 10% or more.

UBS expects Abbott Laboratories (NYSE:ABT) to outperform its competitors in terms of margin expansion and earnings per share growth. The firm pointed out that Abbott’s stock currently trades at roughly 23 times the consensus earnings per share for 2026. Compared to the large-cap MedTech category, which has a higher rate of growth and trades at an average of roughly 28 times projected earnings, this valuation offers a discount.

Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items.

While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.